UPDATE: Baird Downgrades Arcturus Therapeutics (ARCT) to Underperform
Tweet Send to a Friend
(Updated - November 10, 2022 6:08 AM EST)
Baird analyst Joel Beatty downgraded Arcturus Therapeutics (NASDAQ: ARCT) from Neutral ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Baird analyst Joel Beatty downgraded Arcturus Therapeutics (NASDAQ: ARCT) from Neutral ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
